ArticleVaccines2021
Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis.BMJ global health · 2023Pooled it
- Economic analysis of microneedle technology: cost-effectiveness, manufacturing scalability, and commercialization challenges.Drug delivery and translational research · 2026Review
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Development of a microneedle patch for delivery of mRNA-lipid nanoparticles.Drug delivery and translational research · 2026Article
- Booster Immunisation with Skin-Patch-Delivered Unadjuvanted SARS-CoV-2 Spike Protein Vaccine Is Safe and Immunogenic in Healthy Adults.Vaccines · 2025Article
- Advancements in vaccine delivery: harnessing 3D printing for microneedle patch technology.Annals of medicine and surgery (2012) · 2025Review
- Delivery of Islatravir via High Drug-Load, Long-acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus.Advanced healthcare materials · 2025Article
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Respiratory syncytial virus vaccines for toddlers and school-aged children: a pressing necessity for global health.Frontiers in pediatrics · 2025Article
- Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.Molecular biotechnology · 2024Review
- Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.Advanced therapeutics · 2024Article
- The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods.Vaccines · 2024Article
- A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines.Nature biotechnology · 2024Article
- Mechanical Characterization of Dissolving Microneedles: Factors Affecting Physical Strength of Needles.Pharmaceutics · 2024Article
- Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study.Human vaccines & immunotherapeutics · 2023Article
- Three Dimensional Printing and Its Applications Focusing on Microneedles for Drug Delivery.Pharmaceutics · 2023Review
- Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies.Molecular pharmaceutics · 2023Article
- A Sustainable Solution to Skin Diseases: Ecofriendly Transdermal Patches.Pharmaceutics · 2023Review
- Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency.Acta pharmaceutica Sinica. B · 2023Article
- A Review of 3D-Printing of Microneedles.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are an essential component of pandemic preparedness but can be limited due to challenges in production and logistical implementation. While vaccine candidates were rapidly developed against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), immunization campaigns remain an obstacle to achieving herd immunity. Dissolvable microneedle patches are advantageous for many possible reasons: improved immunogenicity; dose-sparing effects; expected low manufacturing cost; elimination of sharps; reduction of vaccine wastage; no need for reconstitution; simplified supply chain, with reduction of cold chain supply through increased thermostability; ease of use, reducing the need for healthcare providers; and greater acceptability compared to traditional hypodermic injections. When applied to coronavirus disease 2019 (COVID-19) and future pandemic outbreaks, microneedle patches have great potential to improve vaccination globally and save many lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.